A cross-border advisory firm built for partner-led deal-making.
PharmaSync was founded on a simple conviction: the next generation of medicines will be moved across borders by people who understand both the science and the deal. We sit between innovators and acquirers, quietly, under NDA, from first conversation to close.
A good cross-border deal is rarely about price alone. It is about finding the partner who can carry an asset further than its originator ever could – and earning enough trust on both sides to make that handover happen.
PharmaSync
Three principles behind every mandate.
We keep engagements small, senior, and confidential. The way we operate is the product – so we hold it to the same standard as the deals we close.
Discretion before everything
Mandates begin under NDA and stay there. Counterparties, terms, and the existence of a process itself are protected until both sides choose to move forward.
- NDA-first engagement
- Named counterparties only
- Quiet, controlled outreach
Senior people, start to finish
The partner who takes your first call runs the diligence, sits in the negotiation, and is in the room at signing. No handoffs to a junior bench halfway through.
- One accountable lead
- Continuity to close
- Direct access throughout
Aligned, not transactional
We structure economics around outcomes, not billable hours. Our incentive is a deal that holds up years later – for both the originator and the acquirer.
- Outcome-based structures
- Both-sides durability
- No fee-table theatre
One integrated team across four markets.
Cairo anchors the firm; Dubai, London, and Boston put senior people in the time zones where cross-border deals get done. The desks share one mandate book – not four.
Cairo
The home desk. Origination, diligence coordination, and the corridor into emerging-market access.
Dubai
Capital relationships and sovereign-backed partners across the GCC and wider Gulf region.
London
European strategics, structuring, and the regulatory bridge between markets.
Boston
US biotech origination, scientific diligence, and access to West-to-East asset flow.
How the firm took shape.
PharmaSync grew deliberately – one desk, one therapeutic area, one corridor at a time.
Founded in Cairo
The firm opens with a single brief – to connect emerging-market access with global innovation, partner-led and under NDA.
The Gulf and London desks
Dubai and London come online, putting capital relationships and European strategics inside the same mandate book as origination.
Boston and the China corridor
The Americas desk opens and the firm formalises its cross-border practice into China biotech, broadening asset flow in both directions.
Full-lifecycle advisory
In-licensing, out-licensing, strategic partnerships, and NewCo formation operate as one integrated practice across all four markets.